Erlotinib is a potent inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase, with single-agent antitumor activity which improves symptom control and quality of life compared with placebo in non-small-cell-lung cancer (NSCLC) patients. We aimed to determine the efficacy and safety of the second, third or fourth-line erlotinib in advanced NSCLC patients in Turkish population. Eighty patients (33 males and 47 females) were retrospectively evaluated. All patients had received a platinum-based regimen as the first-line metastatic therapy. Most of the patients (62.5%) had received erlotinib as the second-line treatment. None of the patients had EGFR mutation studied. One patient achieved a complete response, 10 patients partial response and 21 stable diseases. The overall response rate was 14% and disease control rate was 40%. The median progression-free survival (PFS) and overall survival (OS) were 12 months and 18 months, respectively. Although, there was no survival difference between male and female patients, the median PFS of females was significantly better than male patients (p=0.03). There was no significant difference in disease control rate in terms of age, smoking status, erlotinib line, performance status (PS), stage and skin rash. The most common adverse events were skin rash (56%), diarrhea (9%) and anorexia (8%). Sixteen patients (20%) developed grade 3 toxicities. Grade 4 toxicity or treatment related interstitial lung disease were not observed. Erlotinib showed an acceptable response rate, survival time and toxicity after disease progression with chemotherapy. It's an alternative therapy as a second or third-line therapy in patients with NSCLC. Prospective studies are needed to evaluate the efficiency of the treatment in Turkish population.
INTRODUCTION
Lung cancer is the second most common cancer among men and women and the most common cause of cancer death in the world1. Non-small cell lung cancer (NSCLC) represents about 85% of all lung cancer cases and is generally diagnosed at advanced stage. First line treatment of advanced NSCLC is based on the platinum-doublet chemotherapy with a median overall survival (OS) of about 10-12 months. 2, 3 As the number of patients receiving first-line chemotherapy increases, the need for effective second, third or even fourth-line therapy has been increasing. Advanced NSCLC patients also with poor performance status (PS) tend to have worse response rates and higher risk of toxicities following chemotherapy treatment. 4, 5 Intracellular signaling activated by the EGFR plays a role in tumor growth and progression in cancer and EGFR overexpression is seen in up to 80% of NSCLC6,7. Erlotinib is a potent, orally active, reversible inhibitor of EGFR tyrosine-kinase activity and have received approval for the treatment of advanced NSCLC worldwide. [8] [9] [10] [11] Recently, studies of erlotinib demonstrated promising efficacy and favorable toxicity. [12] [13] [14] In a large, randomised, placebo-controlled, phase III trial (BR.21) in patients with advanced NSCLC who had previously received at least one chemotherapy regimen, erlotinib monotherapy significantly prolonged survival compared with placebo. 8 As compared with placebo, treatment with erlotinib resulted in a significantly longer progression-free survival (PFS) (2.2 vs. 1.8 months; hazard ratio (HR): 0.6; p< 0.001) and OS (6.7 vs. 4.7 months; (HR: 0.70; p< 0.001).
There is no data about erlotinib treatment in NSCLC in Turkey. This retrospective study aimed to determine the efficacy and safety of second, third or fourth-line erlotinib in advanced NSCLC patients regardless of EGFR mutation.
PATIENTS AND METHODS
We retrospectively evaluated the outcome and clinical characteristics of unselected patients treated with erlotinib for advanced NSCLC. Eighty patients with metastatic NSCLC treated with erlotinib 150 mg daily after failure of at least one prior chemotherapy regimen between May 2006 and August 2011 from 9 centers were retrospectively evaluated. Medical records were reviewed to collect demographic data, Eastern Cooperative Oncology Group (ECOG) PS, lung cancer histology, history of tobacco use, metastatic sites, previous chemotherapy, radiotherapy, line of erlotinib treatment, efficacy data and toxicities. Smoking status was defined as never smoker, former smoker (>100 cigarettes in life, but stopped more than six months ago) and current smoker (continuing smoking during the last six months). Although majority of our patients had adenocarcinoma histology, female sex and never smoker due to reimbursement conditions in Turkey, four patients (5%) who were current smoker used the erlotinib as a study drug.
The following factors were evaluated for a potential influence on the response and disease control rate: age (≤40, 40-60 years versus ≥60), gender (male versus female), PS, initial disease stage, smoking status (current smoker versus former smoker/never smoker), histology (adenocarcinoma histology versus others), line of erlotinib treatment and grades of rash (0/1 versus 2+). PFS and OS were calculated after the initiation of erlotinib. 
RESULTS
There were 80 patients: 33 males and 47 females. Demographic data and main characteristics of the patients are shown in Table 1 . Most patients (66%) had ECOG PS 0 and 1 with a predominance of adenocarcinoma histology (91%). All patients had received a platinum-based regimen as the first-line metastatic therapy. Most of the patients (62.5%) had received erlotinib as the second-line treatment.
The most common metastatic sites were bone (31%) and brain (24%). Eighteen patients (23%) had multiple metastatic sites. Six patients (8%) had relapsed after curative surgery and 18 patients (23%) after curative chemoradiotherapy. Sixty-six patients (82.5%) had never smoked. None of the patients had their EGFR mutation status determined.
The median folow-up period was 10 months (range, 2-37) after the beginning of erlotinib treatment. The median duration of erlotinib treatment was 6 months (range, 2-37). One patient had a complete response (CR), 10 patients achieved partial response (PR) and 21 had stable disease (SD). The overall response rate was 14% and disease control rate (DCR=ORR+SD) was 40%. At the time of analysis, there were 32 (40%) deaths and 27 patients (34%) were still on erlotinib. There was no significant difference in DCR in terms of age, smoking status, erlotinib line, PS, initial stage and skin rash but significance was borderline in female patients (female 49% vs. male 27%, p= 0.052).
The median PFS and OS were 12 months (95% CI: 4.22-19.78 months) and 18 months (95% CI:13.34-22.76 months), respectively (Figure 1 and 2) . Analysis of prognostic factors showed that only PS was significantly correlated with OS (p= 0.004). Although, there was no OS difference between male and female patients, the median PFS of females was significantly better than male patients (18 vs. 5 months, p= 0.03, Figure 3 ).
The most common adverse event (AE) was skin rash (56%) ( Table 2 ). Diarrhea (9%) and anorexia (8%) were the other common side effects. Sixteen patients (20%) developed grade 3 toxicities including rash (n= 15, 19%) and diarrhea (n= 1). Grade 4 toxicity or treatment related interstitial lung dise- ase (ILD) were not observed. Due to grade 3 toxicities erlotinib treatment was interrupted in 5 patients (10%) and 3 patients (4%) required dose reductions. All the side effects were improved after dose reductions or delays with no further dose modifications. The median duration of treatment interruptions was 10 days.
DISCUSSION
Only a few options are available for the treatment of patients who are eligible for chemotherapy with disease progression after platin-based chemotherapy for NSCLC. 15 Clearly, new and effective treatments are needed for such patients. The EGFR tyrosine kinase inhibitors gefitinib and erlotinib have been evaluated in several trials. Recently, erlotinib has been investigated in the TRUST study in patients (n= 6665) with advanced stage IIIB/IV NSCLC. 16 CR, PR and SD rates were <1%, 14% and 54%, respectively. Of these, 389 patients (12%) had an erlotinib-related adverse events and only 96 patients (3%) had ≥ grade 3 of AEs. Subgroup analyses demonstrated that PFS and OS were significantly longer in women versus men, in oriental patients versus other ethnic groups, in patients with adenocarcinoma or bronchoalveolar carcinoma ver- sus those with squamous-cell carcinoma, and in never-smokers versus former or current smokers. PFS and OS were also significantly longer in patients with ECOG PS of 0 or 1 versus those with PS of 2 or 3 and in patients who developed erlotinib-related rash compared to those with no rash. The line of treatment (second or third line) was not found to be a prognostic factor for efficacy in the same analysis for the overall population. The findings of TRUST, together with those of BR.21, indicate that erlotinib is as effective as conventional chemotherapy in terms of disease control and survival advantage in patients with advanced NSCLC who had previously failed chemotherapy.
In our study, one patient had a CR, 10 patients achieved PR and 21 had SD, overall DCR (40%) observed in our patients were similar to these of the BR.21 trial. We found that, the median PFS and OS were 12 months (95% CI: 4.22-19.78 months) and 18 months (95% CI:13.34-22.76 months), respectively. These results are better than BR.21 and TRUST data. However, in another retrospective study 17 , median PFS and OS were reported as 4 and 15 months, respectively. Our good results may be due to limitations of the study such as small study population and retrospective nature. Other reasons might be the presence of good prognostic and predictive factors for erlotinib treatment such as adenocarcinoma histology, good PS, female sex and never smokers mentioned in other trials. 8, 16 In several trials, patients with the highest probability of benefit from erlotinib appeared to be females, never smokers, Asian ethnicity with adenocarcinoma histology, with good PS and in patients who developed erlotinib-related rash. 8, 16, 17 In our study, most of the patients (59%) were females, non-smokers (82.5%) with ECOG PS 0 and 1 (66%) and skin rash (56%) who had received erlotinib as the second-line treatment (62.5%). There was no significant difference in the DCR in terms of age, smoking status, erlotinib line, PS, initial stage and skin rash. But, female patients had a marginally better DCR compared to males (49% vs. 27%, p= 0.052). Analysis of prognostic factors showed that only PS was significantly correlated with OS (p= 0.004). Although, there was no OS difference between male and female patients, the median PFS of females was significantly better than male patients (18 vs. 5 months, p= 0.03). Although, none of our patients were tested for EGFR mutation, it's known that female patients have higher EGFR mutation rate. 18 In our study, better efficacy results in females may be explained by the presence of higher rates of EGFR mutations. Therefore, in cases whose EGFR mutation can not be analyzed, these patients should not be excluded from erlotinib treatment.
Skin rash and diarrhea are the most common sideeffects of erlotinib. ILD and pulmonary fibrosis are the SAE's related to erlotinib treatment with an incidence of <1%. 19 In our study, erlotinib had a favorable toxicity profile, and the percentage of patients who required erlotinib dose reductions (4%) was quite low. Erlotinib was generally well tolerated, thus enabling the majority of patients to receive the full therapeutic dose. The most common adverse event was skin rash (56%). Only 16 patients (20%) developed grade 3 toxicities. Grade 4 toxicity or treatment related ILD were not observed. Due to grade 3 toxicities erlotinib treatment was delayed in 5 patients (10%) and 3 patients (4%) required dose reductions. AEs were tolerable and seemed to be equivalent to those in the other population as reported previously, but the incidence of ILD in our study was much lower than that observed in the BR.21 study. Careful management of AEs of erlotinib enables optimum treatment of the patients resulting in increased efficacy.
Rosell et al. 20 analyzed the association between EGFR mutations and the outcome of erlotinib treatment, reporting a PFS of 14 months and overall survival of 27 months in EGFR mutant patients treated with erlotinib. Recently published data from EUR-TAC phase III study 21 (n= 174) demonstrated that, median PFS 9.7 months (95% CI, 8.4-12. 3) in the erlotinib group, compared with 5.2 months (95% CI, 4.5-5.8) in the standard chemotherapy group (p< 0.0001). These studies clearly suggest that EGFR mutations should be determined in patients with NSCLC and only those patients positive for mutations should be considered for treatment with EGFR-TKI. However, we were not able to assess EGFR mutation in any of the patients. Despite this, careful selection of the study population might have probably led to these superior results.
In conclusion, although limited by small numbers and its retrospective design, our study confirmed that erlotinib induces high DCR in pretreated NSCLC patients with manageable side effects. Future prospective studies should include molecular markers together with other biologic and clinical parameters to further improve selection of patients treated with EGFR tyrosine-kinase inhibitors.
